Prostate cancer immunology

Biology, therapeutics, and challenges

W. Scott Webster, Eric J. Small, Brian I. Rini, Eugene D Kwon

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.

Original languageEnglish (US)
Pages (from-to)8262-8269
Number of pages8
JournalJournal of Clinical Oncology
Volume23
Issue number32
DOIs
StatePublished - 2005

Fingerprint

Allergy and Immunology
Immunotherapy
Prostatic Neoplasms
CD27 Antigens
Antigen-Presenting Cells
Prostate
Neoplasms
Therapeutics
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate cancer immunology : Biology, therapeutics, and challenges. / Webster, W. Scott; Small, Eric J.; Rini, Brian I.; Kwon, Eugene D.

In: Journal of Clinical Oncology, Vol. 23, No. 32, 2005, p. 8262-8269.

Research output: Contribution to journalArticle

Webster, W. Scott ; Small, Eric J. ; Rini, Brian I. ; Kwon, Eugene D. / Prostate cancer immunology : Biology, therapeutics, and challenges. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 32. pp. 8262-8269.
@article{d7b422f51ba94381a497002e91a5b0ab,
title = "Prostate cancer immunology: Biology, therapeutics, and challenges",
abstract = "A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.",
author = "Webster, {W. Scott} and Small, {Eric J.} and Rini, {Brian I.} and Kwon, {Eugene D}",
year = "2005",
doi = "10.1200/JCO.2005.03.4595",
language = "English (US)",
volume = "23",
pages = "8262--8269",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "32",

}

TY - JOUR

T1 - Prostate cancer immunology

T2 - Biology, therapeutics, and challenges

AU - Webster, W. Scott

AU - Small, Eric J.

AU - Rini, Brian I.

AU - Kwon, Eugene D

PY - 2005

Y1 - 2005

N2 - A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.

AB - A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=33644697100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644697100&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.4595

DO - 10.1200/JCO.2005.03.4595

M3 - Article

VL - 23

SP - 8262

EP - 8269

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 32

ER -